5 takeaways from Congress’ organ transplant system hearing

Also: The cause of the recent Missouri H5 bird flu case remains a mystery, CDC says

September 12, 2024 Check out STAT+

Sponsored By

NIAID Cause of Missouri H5 bird flu case remains a mystery, CDC says Investigation of first case of human infection without contact with infected animals has yet to reveal a source. Patient recovered without infecting others. By Helen Branswell STAT+ | Gilead's twice-yearly antiviral protects against HIV infection in second large trial Gilead's twice-yearly antiviral, lenacapavir, protected against HIV infection in a study that paves the way for FDA approval. By Elaine Chen STAT+ | Can iTeos and GSK solve TIGIT's troubles? Today's biotech news roundup includes thoughts on hopes for TIGIT and questions about Summit Therapeutics' ivonescimab data in lung cancer. By Adam Feuerstein J. Scott Applewhite/AP 5 takeaways from Congress' hearing on overhauling organ transplant system Surgeons and advocates testify about conflicts of interest, negligence and corruption at OBTN for Congress to address. By Isabella Cueto STAT+ | 'Put him in jail.' Steward CEO de la Torre skips hearing, now Congress is poised to hold him in contempt Lawmakers in Washington turned their focus to the Steward Health Care bankruptcy scandal on Thursday, even as patients, doctors, and regulators across eight states continue to struggle with the hospital chain's financially starved facilities. Senators hoped to grill Steward chief executive Ralph de la Torre at the hearing in the Capitol but had to make do verbally attacking an empty chair. Despite a subpoena, de la Torre refused to appear. By Aaron Pressman and Tal Kopan — Boston Globe STAT+ | Apple will offer millions of AirPod users a hearing aid. Can it convince them to use it? Apple entering the over-the-counter hearing aid market as millions of Americans suffer from mild to moderate hearing loss. By Mario Aguilar and Timmy Broderick Adobe STAT+ | A rare disease program, portrayed as both lifeline and pharma handout, is set to expire Advocates for people with rare diseases say a voucher program has been essential for attracting investment. Others call it a pharma handout. By Jason Mast and John Wilkerson

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser